Skip to main content

Media Releases

Perrigo's media releases will keep you updated on the latest news, product launches, foundation gifts and events across the organization.

Perrigo is one of 36 companies and individuals named as defendants in the most recent complaint filed by various state attorneys general in relation to alleged antitrust violations within the generic pharmaceutical industry. 

A year ago, we launched a new Diversity and Inclusion initiative for Perrigo that stressed the importance of having all members of our community treated with fairness and respect.

Allegan, Michigan and Bronx, New York – April 14, 2020 – Perrigo Company plc is responding to the urgent needs of hospital, medical and first responder personnel who are running dangerously low on medical supplies. Over the next few months, the Company will donate at least 500,000 bottles of hand sanitizer to local hospitals and first responders facing urgent shortages of this essential product.

DUBLIN, Ireland and Allegan, Michigan – April 7, 2020 – Perrigo Company plc and the Perrigo Company Charitable Foundation are donating $400,000 in funding and $216,000 in product donations to assist community partners who are essential to the COVID-19 response effort. Perrigo acted quickly to address the urgent need.

Perrigo Company plc is operating in an unprecedented time for our organization and for the world at large. As we see COVID-19 continue to spread across the countries in which we live and operate, we are mindful that Perrigo has a unique role in this historical situation as the provider of many of the remedies that millions of people are relying on to keep themselves and their families well, to treat their symptoms or ailments, and to help them recover when they fall ill.

Dublin, Ireland and Somerset, N.J. – February 25, 2020 – Perrigo Company plc (NYSE; TASE: PRGO) and its partner, Catalent Pharma Solutions, today announced that the U.S. Food and Drug Administration (FDA) has approved Perrigo’s abbreviated new drug application for generic albuterol sulfate inhalation aerosol, the first AB-rated generic version of ProAir® HFA*. Perrigo is launching a limited quantity of generic albuterol sulfate inhalation aerosol and, in collaboration with its development and manufacturing partner Catalent, is ramping up production to meet future demand.

Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has reached a definitive agreement to acquire the oral care assets of High Ridge Brands for $113 million in cash. The acquisition, which is subject to bankruptcy court approval in connection with High Ridge Brands’ chapter 11 cases, as well as other customary closing conditions, once again demonstrates Perrigo’s commitment to transform to a consumer-focused self-care company and build shareholder value. The transaction is expected to close in the first quarter of 2020.

Perrigo Company plc (NYSE; TASE: PRGO) announced today that its Ranir subsidiary has acquired the assets of Steripod®, a leading toothbrush accessory brand and innovator in the toothbrush protector market, from Bonfit America Inc. The deal includes the Steripod® portfolio of antibacterial toothbrush protectors, kids' products and tongue cleaners. Terms of the deal were not disclosed.

The Perrigo Company Charitable Foundation is proud to announce the donation of a total of $75,000 to Wings of Hope Hospice and Wings Home.

Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has completed the acquisition of the branded over-the-counter (OTC) rights to Prevacid®24HR. 

Press Inquiries

If you are a member of the press on deadline, please reach out to a member of our Global Investor Relations & Corporate Communications team.